<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856154</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT2006-000102-22</org_study_id>
    <secondary_id>EudraCT 2006-000102-22</secondary_id>
    <nct_id>NCT00856154</nct_id>
  </id_info>
  <brief_title>Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection</brief_title>
  <acronym>HIVDCVac</acronym>
  <official_title>Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection. Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I test of concept study: In an attempt to induce new immunity to HIV-1 during untreated
      HIV-1 infection the investigators have identified relatively immune silent immune subdominant
      HLA-A2-restricted HIV-1 CTL epitopes that fit individuals with the HLA-A2 tissue type (about
      50% of peoples in Denmark). Immunising with these conserved epitopes could induce new
      immunity and lower viral load so the patient will live longer before AIDS or Antiviral
      medicine and a lower viral load will limit spread in the population. As adjuvants the
      investigators used patients' own autologous Dendritic Cells generated from blood cells in
      vitro. 12 healthy male HIV-1 infected not in therapy individuals were used for this
      therapeutic vaccination and tested for safety and induction of new cellular CD8 and CD4
      T-cell immunity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: no changes in the blood Hemoglobin, leucocytes, trombocytes, serum sodium,potassium,creatinine,phosphatase, ALAT,ASAT, bilirubin,CRP. No dose limiting toxicity defined as unwanted events defined by CTC version 3 definition as greade 3 or more.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular Immunity induction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptides on autologous Dendritic Cells</intervention_name>
    <description>10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.
Gag150 RLLNAWVKV
Gag433 FLGKIWPV
Env 67 NIWATHACV
Pol606 KLGKAGYVV
Vpu66 ALVEMGHHV
Vif101 GLADQLIHL
Vif23 SLVKHHMYV
Gag298 KRWIILGLNKIVRMY
gp41 VWGIKQLQARVLAVERYLKD
Padre AKXVAAWTLKAAA</description>
    <other_name>Dendritic Cells</other_name>
    <other_name>HIV-1 Peptides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive male

          -  Viral load &gt;1000/ml

          -  CD4 count &gt;300

          -  HLA-A2 tissue type

          -  18-50 years of age

          -  Able to follow the instructions

          -  Informed consent

        Exclusion Criteria:

          -  Treated with other experimental vaccines or immune modulatig medicine

          -  Other chronic infectious diseases

          -  Allergy or autoimmune disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Fomsgaard, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Statens Serum Institut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.laegemiddelstyrelsen.dk</url>
    <description>Danish Medicines Agency</description>
  </link>
  <link>
    <url>http://www.datatilsynet.dk</url>
    <description>Danish register of persons in projects</description>
  </link>
  <link>
    <url>http://www.ssi.dk</url>
    <description>Statens Serum Institut in Denmark (government institution)</description>
  </link>
  <reference>
    <citation>Thorn M, Tang S, Therrien D, Kl√∏verpris H, Vinner L, Kronborg G, Gerstoft J, Corbet S, Fomsgaard A. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS. 2007 Jun;115(6):757-68.</citation>
    <PMID>17550385</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <last_update_submitted>April 7, 2009</last_update_submitted>
  <last_update_submitted_qc>April 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gitte Kronborg / MD DMSc Chief Medical Doctor</name_title>
    <organization>Infectious Disease Department, University Hospital Hvidovre</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HLA-A2</keyword>
  <keyword>Therapeutic</keyword>
  <keyword>Vaccine</keyword>
  <keyword>treatment vaccine</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

